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Chronic cough in children is common and frequently mismanaged. In the past, cough 
was diagnosed as asthma and inappropriate asthma therapies prescribed and esca-
lated. It has been realized that persistent bacterial bronchitis (PBB) is a common cause 
of wet cough and responds to oral antibiotics. The initial definition comprised a history 
of chronic wet cough, positive bronchoalveolar (BAL) cultures for a respiratory pathogen 
and response to a 2-week course of oral amoxicillin–clavulanic acid. This is now termed 
PBB-micro; PBB-clinical eliminates the need for BAL. PBB-extended is PBB-micro or 
PBB-clinical but resolution necessitating 4 weeks of antibiotics; and recurrent PBB is 
>3 attacks of PBB-micro or-clinical/year. However, the airway has only a limited range 
of responses to chronic inflammation and infection, and neutrophilic airway disease is 
seen in many other conditions, such as cystic fibrosis and primary ciliary dyskinesia, 
both chronic suppurative lung disease endotypes, whose recognition has led to huge 
scientific and clinical advances. There is an urgent need to extend endotyping into PBB, 
especially PBB-recurrent. We need to move from associative studies and, in particular, 
deploy sophisticated modern –omics technologies and systems biology, rather as has 
been done in the context of asthma in U-BIOPRED. In summary, the use of the term 
PBB has done signal service in pointing us away from prescribing asthma therapies to 
children with infected airways, but we now need to move beyond a simple description to 
teasing out underlying endotypes.
Keywords: cystic fibrosis, primary ciliary dyskinesia, endotype, airway infection, airway inflammation, 
bronchoalveolar lavage
The history of our understanding and management of chronic cough in children is a litany of 
wrong diagnosis, inappropriate therapy, and muddled thinking. Cough was initially attributed to 
bronchitis, and treated with antibiotics; next it was appreciated that some children who coughed 
also had asthma, and responded to asthma therapy. This led to the catastrophic explosion of asthma 
mis-diagnoses (1–3), when normal children coughing with viral colds were diagnosed as asthmatic, 
and treatment escalated every time they coughed with another cold, despite ample evidence that 
escalating asthma therapy above low-dose inhaled corticosteroids is subject to the law of very rapidly 
diminishing returns (4). Subsequently, systematic studies (5) showed that the commonest cause of 
chronic wet cough was what was termed “persistent bacterial bronchitis” (PBB), many cases of which 
responded to a relatively short course of oral antibiotics. Noteworthy in this paper was that around 
50% of these coughers were given an initial diagnosis of asthma, which was proven correct in less 
than 10%. The response to antibiotics was confirmed in a relatively small randomized controlled 
trial (6), which although a commendable attempt to secure an evidence base, used a cough score (7) 
as an end-point, rather than any more scientific biomarker or objective cough counting. The next 
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consideration became the relationship between PBB and future 
bronchiectasis—would untreated PBB lead to bronchiectasis 
eventually, and would we, with this new paradigm of early and 
aggressive use of antibiotics prevent long term lung damage? I 
return to this important question below.
So, by going back to the future, have we made any progress? Of 
course, it is good that children with chronic airway infection are 
not treated with inhaled corticosteroids, which will likely worsen, 
not improve airway defenses (8–11), and to that extent the term 
PBB has served us very well. But it is now time to move beyond 
this, and this will only happen if weak thinking and general 
complacency about airway disease, and a culture where the so-
called clinical diagnoses and assessments are deemed acceptable 
instead of making objective measurements is filtered out of the 
bloodstream of pediatric pulmonology where it is currently so 
strong. At present, there is little sign that this change is happen-
ing. Here, I advance the proposition that PBB is a description, 
not a diagnosis; and, in 2017, it is an umbrella term of exclusion. 
Failure to appreciate this will lead to scientific bankruptcy; PBB 
should be the start of thinking, not the finish. Elsewhere it has 
been argued that asthma is no more a useful diagnosis than 
arthritis or anemia (12), and I would argue the same is true for 
PBB. Chronic suppurative lung disease (CSLD) is well ahead of 
asthma in terms of defining airway endotypes, but still has a long 
way to go, as exemplified by PBB.
The aim of this annotation is to critically review our concepts 
of PBB, and where we should go next, especially in light of the 
recent ERS statement (13). The aim is to be provocative; so many 
airway diseases are stuck in thought-free ruts, and we need to 
lift our eyes to the towering achievements in those CSLDs which 
have moved out of the rut.
WHAt is PBB?
The initial definition was (i) a history of chronic wet cough, 
(ii) positive bronchoalveolar (BAL) cultures for a respiratory 
pathogen, and (iii) response to a 2-week course of oral amoxi-
cillin–clavulanic acid (5). The definition has been modified, in 
part rightly reflecting the inappropriateness of bronchoscopy 
in many of these children (14). The original definition is now 
termed PBB-micro; PBB-clinical eliminates the need for BAL, 
and overtly acknowledges the need to exclude other causes of 
chronic wet cough, which is implied but not stated in PBB-micro. 
Unfortunately, there is no requirement to try to define infec-
tion non-bronchoscopically, with either cough swabs or better, 
induced sputum which is feasible even in very resource poor 
settings (15) and very young children (15, 16) and gives results 
comparable to BAL. This is a sad exemplar of the current “don’t 
measure” culture of pediatric pulmonology, which is a significant 
omission, as is the absence of any requirement to test if infection 
has resolved with antibiotics. The ERS statement (13) effectively 
defines PBB-clinical as PBB, but allows up to 4 weeks of antibiotics 
to resolve symptoms; again, there is no requirement for positive 
bacteriology. PBB-extended is PBB-micro or PBB-clinical but 
resolution necessitating 4 weeks of antibiotics; and recurrent PBB 
is >3 episodes of PBB/year. As to what investigations should be 
performed to exclude other causes of chronic wet cough, this is 
left to such energy and enthusiasm as may be possessed by the 
treating physician. It is perfectly clear that the infected airway 
signals a problem in stereotypic fashion—wet cough, respiratory 
distress, wheeze related to secretion retention—whether the 
cause be, for example, anatomical airway obstruction, a local 
or systemic immunodeficiency, or any one of many aspiration 
syndromes.
WHAt Are csLD AirWAY eNDOtYPes?
An endotype is a subtype of a condition defined by a distinct 
pathophysiological mechanism (17). The march to CSLD endo-
types started in 1938, when Dorothy Anderson first identified the 
pancreatic disease of cystic fibrosis (CF) (18), thus beginning the 
pathway to the differentiation of CF from other causes of chronic 
wet cough and bronchiectasis. A series of brilliant discoveries has 
led to the determination of the underlying gene defect (19–21) 
and the development of specific diagnostic tests [sweat test 
(22), genotyping (23), transepithelial potential differences (24, 
25)] which make a diagnosis certain in all but the most difficult 
cases; and finally to diagnosis after newborn screening (26). The 
treatment has gone from non-specific therapies directed at the 
downstream consequences of CFTR dysfunction to designer 
molecules correcting the basic defect (27–29), and evidence for 
benefit has come from huge randomized, double-blind controlled 
trials. Finally, the age of personalized medicine in CF is dawning 
with the use of rectal spheroids (30) to determine in  vitro the 
likely response to designer molecules in vivo.
Another obvious CSLD endotype is primary ciliary dyskinesia 
(PCD). From Kartagener’s original description (31) via Afzelius’ 
brilliant linking of electron microscopic abnormalities in sperm 
tails of infertile men with the syndrome (32), thus implicating 
ciliary dysfunction as the primary abnormality, the modern age 
has witnessed an explosion of diagnostic tests (33), including cili-
ary motility, electron microscopy [including electron microscopic 
tomography (34)], genotyping (35), and immunofluorescence of 
ciliary proteins (36). The intricacies of ciliary assembly are being 
unraveled, which has brought the realization that PCD can result 
not just from mutations in ciliary proteins but also in mutations 
in proteins responsible for ciliary assembly (37, 38). As yet 
therapeutic progress has lagged behind, although it is clear that 
some therapies which work well for CF (rhDNase) are useless 
or harmful in most PCD patients (39). The systemic immuno-
deficiencies are also being unraveled, with many specific genetic 
defects emerging from the umbrellas of antibody deficiency and 
common variable immunodeficiency (40).
In summary, the overwhelming message is that the discrimi-
nation of specific CSLD endotypes has led to an explosion of 
progress in the understanding of disease pathophysiology, and is 
likely to lead to novel and highly specific treatments, and which 
will not be possible unless endotypes are defined. Indeed, without 
defining endotypes, progress will not be made and valuable thera-
pies discarded. So in asthma, if Brown had not shown that oral 
prednisolone only worked in wheezy patients with sputum eosin-
ophilia, we would have lost that most efficacious of respiratory 
treatments (41). In later years, the anti-interleukin 5 monoclonal 
mepolizumab would have been discarded as ineffective (42) were 
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it not to have been trialed in a specific group of asthmatics, with 
persistent airway eosinophilia and recurrent acute asthma lung 
attacks (43, 44). Also of note, without appreciating the different 
molecular subclasses of CF, the new molecules would probably 
have been discarded as useless if prescribed for all comers with 
the disease, let  alone all those with a wet cough. So endotype-
based therapy must be the target; where does this leave PBB?
PBB eNDOtYPes?
The broadening of the spectrum of PBB beyond a single episode 
(above) certainly implies different endotypes, and there are 
tantalizing hints from the literature that not all “PBB” is equal. 
A bad outcome (bronchiectasis) is associated with poor response 
to antibiotics (45), recurrent PBB, and isolation of Haemophilus 
Influenzae (46). Clearly a child with a single episode of chronic 
wet cough which responds to a single 2-week course of co-
amoxyclav and never relapses requires no clinical investigation, 
although such children may be a useful control group to compare 
with those requiring multiple antibiotic courses and those who 
progress to bronchiectasis. The child needing prolonged and 
recurrent courses of antibiotics is not merely a diagnostic puzzle 
but also a scientific conundrum; what is the pathophysiology? 
The important question has been raised as to whether PBB is a 
precursor of bronchiectasis. The concept of a pre-bronchiectatic 
state has been proposed (47), and there is much robust evidence 
in favor of it. It is biologically inconceivable that airways can 
pass virtually instantaneously from normal caliber to fixed and 
irreversible dilatation. Indeed, it is clear both from immunodefi-
ciency (48) and CF (49) that there is a phase of airway dilatation 
demonstrable on HRCT and which is reversible. It is also clinical 
experience that the progression of chronic airway infection to 
bronchiectasis can be halted if the underlying cause is remedied, 
for example, an endobronchial foreign body removed or chronic 
aspiration prevented. Hence, clearly for some patients with 
bronchiectasis, there will be a phase indistinguishable from PBB 
preceding airway dilatation, which likely (but unproven) may be 
reversed by intensive treatment.
It is clear that it would be unethical to do true natural history 
studies of chronic productive cough, to see who if untreated 
will progress to bronchiectasis and who eventually resolve their 
symptoms spontaneously. However, children who have had a 
prolonged, undiagnosed productive cough which eventually 
recovered undoubtedly exist in the community, never having 
been referred to secondary care, and should actively be sought 
as a control group. There are important questions we should start 
trying to address. First, does an episode of PBB-clin or -micro 
which responds to a 2-week course of antibiotics and never 
relapses represent a transient immunological insult, for example, a 
viral infection, which when overcome never recurs? Alternatively, 
are there genetic and epigenetic pathways which determine a 
benign, easily treated course despite an underlying mucosal 
immunodeficiency? If such a pathway existed and we understood 
it, might this open up new therapies for the more severe forms of 
the disease? Hypothetically, PBB could arise from infection with 
unusually virulent organisms (for which there is currently no 
evidence, but of course does not exclude the possibility that such 
evidence can be obtained) or an abnormal host response to com-
mon pathogens, and we need better to understand normal and 
pathological mucosal defenses. There are some such studies in the 
literature already (50–52), but we need to move from associative 
studies and, in particular, deploy sophisticated modern –omics 
technologies and systems biology, rather as has been done in the 
context of asthma in U-BIOPRED (53, 54). How can we predict 
who will progress to bronchiectasis? One approach would be to 
determine the immunological, molecular, and –omics signatures 
of established idiopathic bronchiectasis, and see if there is a 
group within the PBB umbrella in whom these signatures can 
be detected, implying they are the true pre-bronchiectatic PBBs. 
What are the biomarkers of progression, and conversely, of a 
response to treatment?
It could be questioned whether invasive approaches are ethical 
and appropriate in very young children. However, it should be 
noted that bronchoscopy, BAL lavage, endobronchial biopsy, and 
bronchial brushings are all acceptable diagnostic procedures in 
young children. I would argue that it is rather unethical to give 
prolonged and recurrent courses of antibiotics to young children 
without making every effort to establish the underlying diagnosis. 
Clearly, a single episode of PBB responding to a 2-week treatment 
course of oral antibiotics and never recurring does not merit 
invasive investigation, but how many courses, and for how long, 
would the pediatric community feel happy to administer “blind”? 
I would argue that currently we are too ready to sleep walk into 
more and more antibiotics without looking for specific diagnoses 
much more intensely.
tWeNtY-First ceNtUrY treAtMeNt 
OF PBB?
There is much scope for improvement of the current manage-
ment of PBB, assuming that other underlying causes have been 
excluded. The presence of a wet cough and palpable secretions 
within the airway can be established clinically. However, whether 
this is due to bacterial infection cannot be, and every effort should 
be made to obtain lower airway cultures non-invasively. Second, 
cough and its frequency are poorly appreciated by parents and 
children (55) and we should surely objectively measure cough 
frequency over 24 h with one of a number of counters (56, 57). 
Validated questionnaires (7) are of course a step forward, but 
should not be a substitute for direct measurement. If antibiotics 
are prescribed, these steps should be repeated to ensure that infec-
tion has cleared. If there is relapse, it is essential to re-evaluate the 
diagnosis, as well as repeating the basic measurements (above). 
The point at which more detailed investigation, including bron-
choscopy should be performed, and the role of airway clearance 
and mucolytics, particularly in preventing recurrence, needs to 
be explored. The pervasive “no-measurement” culture needs to 
be tackled firmly in PBB as elsewhere.
sUMMArY AND cONcLUsiON
It is clear that in the past, the umbrella term PBB has done 
signal service, not least in preventing the over-use of inhaled 
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corticosteroids in children with a chronic wet cough. But it is 
also clear that it is only a staging post, and that we need to define 
PBB endotypes and move to specific treatments in particular in 
those who have PBB-extended and PBB-recurrent, including 
defining those at high risk of progressing to bronchiectasis. The 
time is right for a much more detailed and sophisticated assault 
on the underlying pathophysiology. Finally, we must avoid the 
treatment of PBB repeating the mistakes of history. Children were 
(and are) treated with inhaled corticosteroids for eosinophilic 
airway inflammation with no attempt to demonstrate that airway 
inflammation was actually present, and with bronchodilators 
without seeing if there was true reversible airway obstruction due 
to constriction of airway smooth muscle; too often we have given 
these treatments and believed the patient’s subjective impressions. 
This is akin to prescribing insulin without making any attempt to 
make measurements of blood glucose homeostasis. And yet all of 
the current PBB definitions include treatment with antibiotics, 
without mandating attempts to determine that (a) infection is 
present in the first place, (b) that infection has resolved, and (c) 
that cough frequency has returned to normal. This is not a toler-
able standard of care in the twenty-first century. We should be 
looking at the dizzy heights reached in CF and move to emulate 
them in PBB.
AUtHOr cONtriBUtiONs
The author confirms being the sole contributor of this work and 
approved it for publication.
FUNDiNG
AB is an NIHR Senior Investigator and additionally was sup-
ported by the NIHR Respiratory Disease Biomedical Research 
Unit at the Royal Brompton and Harefield NHS Foundation Trust 
and Imperial College London.
reFereNces
1. Bush A, Fleming L. Is asthma overdiagnosed? Arch Dis Child (2016) 101:688–9. 
doi:10.1136/archdischild-2015-309053 
2. Looijmans-van den Akker I, van Luijn K, Verheij T. Overdiagnosis of asthma 
in children in primary care: a retrospective analysis. Br J Gen Pract (2016) 
66:e152–7. doi:10.3399/bjgp16X683965 
3. Aaron SD, Vandemheen KL, FitzGerald JM, Ainslie M, Gupta S, Lemière C, 
et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. 
JAMA (2017) 317:269–79. doi:10.1001/jama.2016.19627 
4. Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, 
et  al. Step-up therapy for children with uncontrolled asthma receiving 
inhaled corticosteroids. N Engl J Med (2010) 362:975–85. doi:10.1056/
NEJMoa1001278 
5. Marchant JM, Masters IB, Taylor SM, Cox NC, Seymour GJ, Chang AB. 
Evaluation and outcome of young children with chronic cough. Chest (2006) 
129:1132–41. doi:10.1378/chest.129.5.1132 
6. Marchant J, Masters IB, Champion A, Petsky H, Chang AB. Randomised 
controlled trial of amoxycillin clavulanate in children with chronic wet cough. 
Thorax (2012) 67:689–93. doi:10.1136/thoraxjnl-2011-201506 
7. Chang AB, Newman RG, Carlin JB, Phelan PD, Robertson CF. Subjective 
scoring of cough in children: parent-completed vs child-completed diary 
cards vs an objective method. Eur Respir J (1998) 11:462–6. doi:10.1183/09
031936.98.11020462 
8. Sabroe I, Postma D, Heijink I, Dockrell DH. The yin and the yang of 
immunosuppression with inhaled corticosteroids. Thorax (2013) 68:1085–7. 
doi:10.1136/thoraxjnl-2013-203773 
9. Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled cortico-
steroids and the risk of tuberculosis. Thorax (2013) 68:1105–13. doi:10.1136/
thoraxjnl-2012-203175 
10. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in 
chronic obstructive pulmonary disease and the risk of hospitalization for 
pneumonia. Am J Respir Crit Care Med (2007) 176:162–6. doi:10.1164/
rccm.200611-1630OC 
11. Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW. 
Chronic respiratory disease, inhaled corticosteroids and risk of non-tu-
berculous mycobacteriosis. Thorax (2013) 68:256–62. doi:10.1136/
thoraxjnl-2012-201772 
12. Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, et al. After 
asthma – redefining airways diseases. A Lancet commission. Lancet (2017). 
doi:10.1016/S0140-6736(17)30879-6 
13. Kantar A, Chang AB, Shields MD, Marchant JM, Grimwood K, Grigg J, et al. 
ERS statement on protracted bacterial bronchitis in children. Eur Respir J 
(2017) 50(2):1602139. doi:10.1183/13993003.02139-2016 
14. Chang AB, Upham JW, Masters B, Redding GR, Gibson PG, Marchant JM, 
et  al. Protracted bacterial bronchitis: the last decade and the road ahead. 
Pediatr Pulmonol (2016) 51:225–42. doi:10.1002/ppul.23351 
15. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus 
gastric lavage for microbiological confirmation of pulmonary tuberculosis 
in infants and young children: a prospective study. Lancet (2005) 365:130–4. 
doi:10.1016/S0140-6736(05)17702-2 
16. Jochmann A, Artusio L, Robson K, Nagakumar P, Collins N, Fleming L, et al. 
Infection and inflammation in induced sputum from preschool children with 
chronic airways diseases. Pediatr Pulmonol (2016) 51:778–86. doi:10.1002/
ppul.23366 
17. Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. 
Asthma endotypes: a new approach to classification of disease entities 
within the asthma syndrome. J Allergy Clin Immunol (2011) 127:355–60. 
doi:10.1016/j.jaci.2010.11.037 
18. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac 
disease. Am J Dis Child (1938) 56:344–99. doi:10.1001/archpedi.1938. 
01980140114013 
19. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, et al. 
Identification of the cystic fibrosis gene: chromosome walking and jumping. 
Science (1989) 245:1059–65. doi:10.1126/science.2772657 
20. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, 
et al. Identification of the cystic fibrosis gene: genetic analysis. Science (1989) 
245:1073–80. doi:10.1126/science.2570460 
21. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. 
Identification of the cystic fibrosis gene: cloning and characterization of com-
plementary DNA. Science (1989) 245:1066–7. doi:10.1126/science.2475911 
22. Gibson LE, di Sant’Agnese PA. A note on studies of salt excretion in sweat: 
relationships between rate, conductivity, and electrolyte composition of sweat 
from patients with cystic fibrosis and from control subjects. J Pediatr (1963) 
62:855–67. doi:10.1016/S0022-3476(63)80099-2 
23. Sosnay PS, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, et al. Defining 
the disease liability of variants in the cystic fibrosis transmembrane conduc-
tance regulator gene. Nat Genet (2013) 45:1160–7. doi:10.1038/ng.2745 
24. Rowe SM, Clancy JP, Wilschanski M. Nasal potential difference measurements 
to assess CFTR ion channel activity. Methods Mol Biol (2011) 741:69–86. 
doi:10.1007/978-1-61779-117-8_6 
25. Hug MJ, Derichs N, Bronsveld I, Clancy JP. Measurement of ion trans-
port function in rectal biopsies. Methods Mol Biol (2011) 741:87–107. 
doi:10.1007/978-1-61779-117-8_7 
26. Barben J, Castellani C, Dankert-Roelse J, Gartner S, Kashirskaya N, Linnane B, 
et  al. The expansion and performance of national newborn screening 
programmes for cystic fibrosis in Europe. J Cyst Fibros (2017) 16:207–13. 
doi:10.1016/j.jcf.2016.12.012 
5Bush Endotypes of PBB
Frontiers in Pediatrics | www.frontiersin.org December 2017 | Volume 5 | Article 264
27. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A 
CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N 
Engl J Med (2011) 365:1663–72. doi:10.1056/NEJMoa1105185 
28. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, 
et  al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous 
for Phe508del CFTR. N Engl J Med (2015) 373:220–31. doi:10.1056/
NEJMoa1409547 
29. Donaldson SH, Pilewski JM, Griese M, Cooke J, Viswanathan L, Tullis E, 
et  al. Tezacaftor/ivacaftor in subjects with cystic fibrosis and F508del/
F508del-CFTR or F508del/G551D-CFTR. Am J Respir Crit Care Med (2017). 
doi:10.1164/rccm.201704-0717OC 
30. Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, 
et  al. Characterizing responses to CFTR-modulating drugs using rectal 
organoids derived from subjects with cystic fibrosis. Sci Transl Med (2016) 
8:344ra84. doi:10.1126/scitranslmed.aad8278 
31. Kartagener M. Zur Pathogenese der Bronchiektasien. I. Mitteilung: 
Bronchiektasien bei Situs viscerum inversus. Beiträge zur Klinik und 
Erforschung der Tuberkulose und der Lungenkrankenheiten. (Vol. 83), (1933). 
p. 489–501.
32. Afzelius BA. A human syndrome caused by immotile cilia. Science (1976) 
193:317–9. doi:10.1126/science.1084576 
33. Lucas JS, Barbato A, Collins SA, Goutaki M, Behan L, Caudri D, et al. European 
Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. 
Eur Respir J (2017):49:1601090. doi:10.1183/13993003.01090-2016 
34. Shoemark A, Hogg C. Electron tomography of respiratory cilia. Thorax (2013) 
68:190–1. doi:10.1136/thoraxjnl-2012-202938 
35. Collins SA, Walker WT, Lucas JS. Genetic testing in the diagnosis of primary 
ciliary dyskinesia: state-of-the-Art and future perspectives. J Clin Med (2014) 
3:491–503. doi:10.3390/jcm3020491 
36. Shoemark A, Frost E, Dixon M, Ollosson S, Kilpin K, Patel M, et al. Accuracy 
of immunofluorescence in the diagnosis of primary ciliary dyskinesia. Am 
J Respir Crit Care Med (2017) 196:94–101. doi:10.1164/rccm.201607-1351OC 
37. Marshall CB, Mays DJ, Beeler JS, Rosenbluth JM, Boyd KL, Santos Guasch 
GL, et  al. p73 is required for multiciliogenesis and regulates the Foxj1-
associated gene network. Cell Rep (2016) 14:2289–300. doi:10.1016/j.celrep. 
2016.02.035 
38. Olcese C, Patel MP, Shoemark A, Kiviluoto S, Legendre M, Williams HJ, et al. 
X-linked primary ciliary dyskinesia due to mutations in the cytoplasmic 
axonemal dynein assembly factor PIH1D3. Nat Commun (2017) 8:14279. 
doi:10.1038/ncomms14279 
39. O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic 
bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study 
Group. Chest (1998) 113:1329–34. doi:10.1378/chest.113.5.1329 
40. Yazdani R, Hakemi MG, Sherkat R, Homayouni V, Farahani R. Genetic defects 
and the role of helper T-cells in the pathogenesis of common variable immu-
nodeficiency. Adv Biomed Res (2014) 3:2. doi:10.4103/2277-9175.124627 
41. Brown HM. Treatment of chronic asthma with prednisolone; significance 
of eosinophils in the sputum. Lancet (1958) 2(7059):1245–7. doi:10.1016/
S0140-6736(58)91385-0 
42. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, et al. 
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, 
airway hyper-responsiveness, and the late asthmatic response. Lancet (2000) 
356:2144–8. doi:10.1016/S0140-6736(00)03496-6 
43. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, 
Pizzichini E, et  al. Mepolizumab for prednisone-dependent asthma with 
sputum eosinophilia. N Engl J Med (2009) 360:985–93. doi:10.1056/
NEJMoa0805435 
44. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. 
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl 
J Med (2009) 360:973–84. doi:10.1056/NEJMoa0808991 
45. Goyal V, Grimwood K, Marchant J, Masters IB, Chang AB. Does failed chronic 
wet cough response to antibiotics predict bronchiectasis? Arch Dis Child 
(2014) 99:522–5. doi:10.1136/archdischild-2013-304793 
46. Wurzel DF, Marchant JM, Yerkovich ST, Upham JW, Petsky HL, Smith-
Vaughan H, et al. Protracted bacterial bronchitis in children: natural history 
and risk factors for bronchiectasis. Chest (2016) 150:1101. doi:10.1016/j.
chest.2016.06.030 
47. Eastham KM, Fall AJ, Mitchell L, Spencer DA. The need to redefine non-cystic 
fibrosis bronchiectasis in childhood. Thorax (2004) 59:324–7. doi:10.1136/
thx.2003.011577 
48. Gaillard EA, Carty H, Heaf D, Smyth RL. Reversible bronchial dilatation in 
children: comparison of serial high-resolution computer tomography scans of 
the lungs. Eur J Radiol (2003) 47:215–20. doi:10.1016/S0720-048X(02)00122-5 
49. Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, et al. Risk 
factors for bronchiectasis in children with cystic fibrosis. N Engl J Med (2013) 
368:1963–70. doi:10.1056/NEJMoa1301725 
50. Marchant JM, Gibson PG, Grissell TV, Timmins NL, Masters IB, Chang AB. 
Prospective assessment of protracted bacterial bronchitis: airway inflam-
mation and innate immune activation. Pediatr Pulmonol (2008) 43:1092–9. 
doi:10.1002/ppul.20906 
51. Chang AB, Yerkovich ST, Gibson PG, Anderson-James S, Petsky HL, Carroll ML, 
et al. Pulmonary innate immunity in children with protracted bacterial bron-
chitis. J Pediatr (2012) 161:621–5. doi:10.1016/j.jpeds.2012.03.049 
52. Baines KJ, Upham JW, Yerkovich ST, Chang AB, Marchant JM, Carroll M, 
et al. Mediators of neutrophil function in children with protracted bacterial 
bronchitis. Chest (2014) 146:1013–20. doi:10.1378/chest.14-0131 
53. Kuo CS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, et  al. A tran-
scriptome-driven analysis of epithelial brushings and bronchial biopsies to 
define asthma phenotypes in U-BIOPRED. Am J Respir Crit Care Med (2017) 
195:443–55. doi:10.1164/rccm.201512-2452OC 
54. Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An inte-
grative systems biology approach to understanding pulmonary diseases. Chest 
(2010) 137:1410–6. doi:10.1378/chest.09-1850 
55. Hamutcu R, Francis J, Karakoc F, Bush A. Objective monitoring of cough in 
children with cystic fibrosis. Pediatr Pulmonol (2002) 34:331–5. doi:10.1002/
ppul.10174 
56. Birring SS, Fleming T, Matos S, Raj AA, Evans DH, Pavord ID. The 
Leicester Cough Monitor: preliminary validation of an automated cough 
detection system in chronic cough. Eur Respir J (2008) 31:1013–8. 
doi:10.1183/09031936.00057407 
57. Kelsall A, Houghton LA, Jones H, Decalmer S, McGuinness K, Smith JA. A 
novel approach to studying the relationship between subjective and objective 
measures of cough. Chest (2011) 139:569–75. doi:10.1378/chest.10-0438 
Conflict of Interest Statement: The author declares that the research was 
conducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2017 Bush. This is an open-access article distributed under the terms 
of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
